Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Pharming cijfers 7 nov

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,835 20 mei 2024 17:35
  • 0,000 (0,00%) Dagrange 0,834 - 0,849
  • 3.568.700 Gem. (3M) 6,5M

Pharming cijfers 7 nov

613 Posts
Pagina: 1 2 3 4 5 6 ... 31 »» | Laatste | Omlaag ↓
  8. stormvogel 7 november 2013 07:43
    do 07 nov 2013, 07:22

    Verlies Pharming neemt af

    LEIDEN (AFN) - Pharming heeft in de eerste 9 maanden van het jaar zijn verlies zien afnemen. Dat bleek donderdag uit het tussentijdse handelsbericht van het biotechnologiebedrijf.

    Pharming 06-11-2013 (17:37)
    0,125EUR+% +
    grafiek
    Naar Pharming detailpagina

    Pharming rapporteerde een verlies van 11,1 miljoen euro. Dat was in dezelfde periode een jaar eerder nog 24,2 miljoen euro. De omzet nam toe naar 6 miljoen euro, van 2,4 miljoen euro een jaar terug. Dat kwam voornamelijk door een forse mijlpaalbetaling van partner Santarus.

    De negatieve vermogenspositie van Pharming kwam aan het eind van het derde kwartaal uit op 1,6 miljoen euro, met een kaspositie van 13,5 miljoen euro. Het bedrijf bekijkt ,,verschillende opties'' om het negatieve eigen vermogen te verminderen en terug te keren naar een positief eigen vermogen.

    De operationele kosten van de onderneming daalden in de eerste 9 maanden van het jaar tot 9,3 miljoen euro, van 17,9 miljoen euro een jaar eerder
  11. stormvogel 7 november 2013 07:50

    Pharming Reports On Financial Results For The First Nine Months Of 2013

    Leiden, The Netherlands, 7 November 2013. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) today published its financial report for the first nine months of 2013.

    FINANCIAL HIGHLIGHTS

    •Revenues and other income increased to €6.0 million (9M 2012: €2.4 million), mainly as a result of a US$ 5 million (€3.8 million) milestone payment by our US partner Santarus on the receipt of FDA acceptance for review of the BLA for Ruconest;

    •Operating costs from continuing operations decreased to €9.3 million (9M 2012: €17.9 million), driven by reductions following the 2012 restructuring and lowering of project costs regarding Ruconest®;

    •Financial income and expenses increased to €7.4 million (9M 2012: €5.5 million), primarily as a result of non-cash financial costs relating to the January 2013 €16.35 million convertible bond (2012 costs mainly related to the €8.0 million 2012 convertible bond);

    •The net loss decreased to €11.1 million (9M 2012 €24.2 million), including the €7.4 million (9M 2012: €5.5 million) of net financing loss;

    •Net cash outflows from operations decreased to €7.1 million (9M 2012: €11.6 million) while net cash inflows from financing activities amounted to €14.2 million (including €16.0 million from the issue of convertible bonds) and net cash inflows from investing activities amounted to €0.2 million received upon transfer of an intangible fixed asset;

    •Cash at the end of the third quarter of 2013 amounted to €13.5 million (2012 FY: €6.3 million). The negative equity position decreased to €1.6 million from €7.7 million at year end 2012;

    •Post events: On 1 October, the Company re-deeemed the final tranche (€2.35 million) of the January 2013 Convertible Bond in cash. On 9 October the Company announced a €12.0 million private placement with institutional investors. As a result of this private placement, Pharming’s equity position has become positive again for the first time since December 2011;

    •A reverse share split 10:1 was approved at the EGM of 28 February 2013. The total number of shares as of today, 7 November 2013 is 332,434,319.

    OPERATIONAL HIGHLIGHTS

    •Biologics License Application (BLA) for RUCONEST® was filed and subsequently accepted by the US Food and Drug Administration (FDA)
    ?Pharming and Santarus are seeking U.S. marketing approval of RUCONEST® for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE);

    ?Pharming and Santarus were recently informed by the FDA that an Advisory Committee is not likely to be required as part of the RUCONEST review;

    ?Pharming and Santarus expect the FDA will complete its review or otherwise respond to the RUCONEST® BLA by 16 April 2014.

    •European Medicines Agency (EMA) provided approval for Sanofi Chimie, Pharming’s Contract Manufacturing Organization partner, to manufacture drug substance for Pharming’s product RUCONEST® at their Aramon (France) site, completing an important up-scaling of the production capacity that will allow for future significant economies of scale.

    •New data from a pivotal Phase III clinical study (Study 1310) of RUCONEST® for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) featured in a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy.

    •Results of a study demonstrating that RUCONEST® has been shown to have a beneficial effect as a donor pre-treatment therapy in an animal model of kidney transplantation was presented at the American Transplant Congress in Seattle, Washington.

    •The Company entered into a strategic collaboration in China with Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company, for the development, manufacture and commercialisation of new products at SIPI, funded by SIPI upto IND stage, based on the Pharming technology platform. In addition, Pharming has also granted SIPI an exclusive license to commercialise RUCONEST® (conestat alfa) in China.

    •For HAE prophylaxis, we submitted, under our investigational new drug application, a protocol to the FDA with a request for a special protocol assessment, or SPA. The FDA has indicated that modifications to the protocol are needed before proceeding with the study and further discussions will be required in order for the protocol to be approved pursuant to the SPA process. We and Santarus are evaluating next steps to move the program forward.

    Sijmen De Vries, Chief Executive of Pharming commented: “During the third quarter we have continued to build on the positive momentum experienced in the first six months of 2013; momentum which allowed us to further strengthen our balance sheet through a successful €12.0 million private placement with institutional investors, completed directly after closing of the third quarter. This was an important event for Pharming: as well as strengthening of our balance sheet, the placement demonstrated the continued support of our existing institutional shareholders as well providing new institutional shareholders with the opportunity to take a position in Pharming. Significantly, the private placing occurred after we fully redeemed the January 2013 Convertible Bond. Together with our US partner Santarus, our team continues to work on the ongoing FDA review of RUCONEST® and in this context we are pleased to note today that the FDA has recently informed us that an Advisory Committee is not likely to be required as part of the RUCONEST® review.

  12. stormvogel 7 november 2013 07:51
    FINANCIAL RESULTS

    In the nine months to 30 September 2013 the Company generated revenue and other income of €6.0 million (9M 2012: €2.4 million). This increase results from a license fee following achievement of the US$ 5 million milestone from our US partner Santarus for FDA acceptance for review of our BLA for Ruconest. Product sales in the nine months of 2013 amounted to €0.6 million, of which €0.4 million came in during the third quarter (€0.8 million 9M 2012). Costs of revenues amounted to € 0.4 million in the first nine months of 2013 compared to €0.8 million in the same period of 2012. In the first nine months of 2012, there was an inventory impairment of €2.3 million, while there were no impairments in 2013.

    Total operating costs in the first nine months of 2013 decreased to €9.3 million from €17.9 million in the same period in 2012. Research and development costs decreased by €6.7 million to €7.4 million in the first nine months of 2013 from €14.1 million in the same period of 2012, which reflects reduced human capital costs following the restructuring in 2012, as well as lower costs related to clinical study 1310 and other cost savings. General and administrative costs decreased by €0.7 million to €1.6 million in the first nine months of 2013 compared to the first nine months of 2012, mainly as a result of the restructuring in 2012. In the first nine months of 2013, there were no impairment charges while these amounted to €1.2 million in the same period of 2012.

    On 16 January 2013, the Company entered into a 8.5% convertible bond transaction of €16.35 million convertible bonds plus 16,349,999 warrants that was approved at the EGM of 28 February 2013. The bonds were repayable in cash and/or in shares in seven installments until 1 October 2013. In the first nine months of 2013, five installments were repaid in shares and one installment in cash. The seventh installment has been redeemed in cash subsequent to the reporting period, on 1 October 2013. With regards to these pay-backs in shares, the Company issued a total of 127,369,529 shares in the first nine months of 2013. Financial income in the first nine months of 2013 amounts to €0.6 million compared to €1.7 million in the same period of 2012. Financial income is non-cash in both periods and is exclusively related to decreases in the fair value of derivative financial liabilities.

    As a result of the above items, net loss for the first nine months of 2013 decreased to €11.1 million from €24.2 million in the same period of 2012.

    FINANCIAL POSITION

    Total cash and cash equivalents (including restricted cash) increased to €13.5 million at 30 September 2013 from €6.3 million at year end 2012. The increase follows from net cash outflows from operations of €7.1 million with net cash inflows from financing activities amounting to €14.2 million and net cash inflows from investing activities amounting to €0.2 million. Financing cash flows mainly result from the 2013 issue of convertible bonds which raised gross €16.0 million in cash.

    NEGATIVE EQUITY

    The Company has negative equity since December 2011. The negative equity position at 30 September 2013 amounts to €1.6 million, a decrease of €6.2 million compared to 31 December 2012. The decrease is a result of new equity issues related to the 2013 convertible bonds in the first nine months of 2013, partially offset by the net loss for the period.
    The negative equity position has in itself no immediate impact on the execution of Pharming’s business plan, nor does it imply that the Company is legally required to issue new share capital. However, the Company is considering various options in order to reduce the negative equity and return to a positive equity position.

    About RUCONEST® and Hereditary Angioedema
    RUCONEST (INN conestat alfa) is a recombinant version of the human protein C1 esterase inhibitor, and is produced with Pharming's proprietary transgenic technology. RUCONEST is approved in Europe for the treatment of acute angioedema attacks in patients with HAE, a genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 esterase inhibitor, resulting in unpredictable and debilitating episodes of intense swelling. The swelling may occur in one or more anatomical areas, including the extremities, face, trunk, genitals, abdomen and upper airway. The frequency and severity of HAE attacks vary and are most serious when they involve laryngeal edema, which can close the upper airway and cause death by asphyxiation. According to the U.S. Hereditary Angioedema Association, epidemiological estimates for HAE range from one in 10,000 to one in 50,000 individuals. RUCONEST is an investigational drug in the U.S. and has been granted orphan drug designation by the FDA both for the treatment of acute attacks of HAE and for prophylactic treatment of HAE.

    About Pharming Group NV
    Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Santarus, Inc. (NASDAQ: SNTS) in North America and a Biologics License Application (BLA) for RUCONEST® is under review by the U.S. Food and Drug Administration. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell based technologies. In July 2013, the Platform was partnered with Shanghai Institute for Pharmaceutical Industry (SIPI), a Sinopharm Company, for joint global development of new products. Pre- clinical development and manufacturing will take place at SIPI and are funded by SIPI. Pharming and SIPI initially plan to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.

    This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

    Contact
    Sijmen de Vries, CEO: T: +31 71 524 7400
  13. arreno 7 november 2013 07:54
    quote:

    Olli-Street schreef op 7 november 2013 07:33:

    ziet er volgens mij niet goed (genoeg) uit ... wederom door het putje ! zit er helaas historisch in aan 0.23 dus aktueel 2.3 euro :-(
    Dit komt nooit goed.
    ben ik met je eens, maar het zou me niet verbazen als de kudde daar anders over denkt en de koers zal stijgen.
  19. stormvogel 7 november 2013 08:36

    Datum meldingsplicht:
    05 nov 2013

    Meldingsplichtige:
    Sabby Healthcare Volatility Master Fund, Ltd.

    Uitgevende instelling:
    Pharming Group N.V.

    Inschrijving handelsregister:
    28048592

    Certificaat van aandeel 15.299.145,00 15.299.145,00 Reëel Reëel Rechtstreeks
    Warrant 3.824.786,00 0,00 Potentieel Potentieel Rechtstreeks

    Procentuele verdeling (longpositie)

    Kapitaalbelang 4,60 % 4,60 % 0,00 % 0,00 % 0,00 %
    Stemrecht 4,60 % 4,60 % 0,00 % 0,00 % 0,00 %
613 Posts
Pagina: 1 2 3 4 5 6 ... 31 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Markt lijkt groeipotentieel Pharming te onderschatten

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 10 mei RBC verlaagt koersdoel Pharming
  2. 08 mei Update: Flinke omzetstijging Pharming 2
  3. 08 mei AEX houdt 900 punten waarschijnlijk niet vast, zorgen Ahold, Pharming en SBM voor spektakel? 2
  4. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  5. 18 apr Pharming rondt plaatsing obligaties af 5
  6. 18 apr Pharming vervangt converteerbare lening 6
  7. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  8. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  9. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?
  10. 14 mrt Pharming rekent ook voor 2024 op dubbelcijferige omzetgroei 2

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!